Search

The influence of immobilized proteases such as catalytin (a complex preparation containing the protease terrilytin and the antiseptic catapol) and streptodecase (an activator of fibrinolysis proteases) on the humoral immune response induced by the thymus-dependent antigen (SRBC) under conditions of burns and Staphylococcus infected burns was studied. The immobilized proteases catalytin and streptodecase had an immunostimulating effect under conditions of extended burns. Catalytin had an immunocorrigating effect under conditions of the infected burns. It was suggested that the complex enzyme-containing preparation catalytin and the immobilized activator of fibrinolysis proteases streptodecase were promising immunopharmacological agents in combined treatment of pathological processes accompanied by the development of immune deficiency as a secondary condition.

Systemic thrombolytic therapy was given to 67 patients with large-focal myocardial infarction: immobilized streptokinase (streptodecase) was administered to 37 patients, and native thrombolytic drugs (streptokinase or urokinase), to 30 patients. Systemic thrombolytic therapy initiated within 6 hours of the attack was shown to affect favorably the course of myocardial infarction, as manifested in a significant reduction of the incidence of protracted disease and arrhythmias, and rapid elimination of congestive heart failure. The two regimens being equally effective in clinical terms, immobilized streptokinase was associated with considerably reduced rates of specific side-effects common to thrombolytic therapy.

The usefulness of the thrombolytic therapy in diseases of the cardio-vascular system, complicated or caused by thromboses is beyond doubt. However, the existing medicinal forms of fibrinolytic enzymes possess a number of disadvantages which limit their use. To enhance the efficacy of thrombolytic therapy a streptokinase, named streptodekase, has been created and immobilized on a water-soluble matrix. Streptodekase was tested on the haemocoagulation system in 7 patients with thrombosis of the femoral artery or the branches of the pulmonary artery. It was seen that streptodekase causes a considerable and rapid increase of fibrinolysis without unwanted disorders in the blood coagulation and other side effects. The convenience in use and simplicity (the therapeutic dose of 3,000,000 units is administered in a single injection, intravenously and immediately), the safety and high specific activity permit one to think that the drug may be widely used.

Streptodecase was used in experiments and in clinical practice for treatment of intraocular traumatic hemorrhages. The enzyme, at a dose of 30,000-45,000 .un, did not exhibit any toxico-allergic effects on eye tissues and caused maximal lysis of the blood clot. 114 patients were treated with the enzymatic preparation and in 60% of the patients blood, liberated into vitreous body, was completely lysed.